Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | TSHR | P16473 | 3/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA3 | P07451 | 2/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | CA6 | P23280 | 2/20 | 0.50 |
| ▸ | CA5A | P35218 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.50 |
| ▸ | TYR | P14679 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8059670 | 0.81 | ALDH1A1 (0.56) | ALDH1A1TSHRTP53SRD5A2KMT2A | |
| Terephthalic Acid SCHEMBL4612225 | 0.79 | TSHR (0.67) | ALDH1A1TSHRTP53SRD5A2KMT2A | |
| SCHEMBL70166 | 0.79 | TSHR (0.67) | ALDH1A1TSHRTP53SRD5A2KMT2A | |
| SCHEMBL68390 | 0.79 | SRD5A2 (0.69) | ALDH1A1TSHRTP53SRD5A2KMT2A | |
| SCHEMBL2643786 | 0.78 | PLA2G10 (0.57) | ALDH1A1TSHRKMT2ACA1CA2 | |
| SCHEMBL2642382 | 0.78 | KMT2A (0.67) | KMT2ASMN1; SMN2GAAMAPTL3MBTL1 | |
| SCHEMBL10965462 | 0.78 | CA12 (0.70) | ALDH1A1TSHRTP53SRD5A2KMT2A | |
| SCHEMBL1604682 | 0.78 | ALDH1A1 (0.58) | ALDH1A1TSHRTP53SRD5A2KMT2A | |
| Terephthalic Acid SCHEMBL175823 | 0.78 | TSHR (1.00) | ALDH1A1TSHRTP53SRD5A2CA1 | |
| Terephthalic Acid SCHEMBL5053781 | 0.78 | TSHR (1.00) | ALDH1A1TSHRTP53SRD5A2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3154941-B1 | SMALL MOLECULE LFA-1 INHIBITORS | ALLOCYTE PHARMACEUTICALS AG (CH) | 2021-01-20 | — | — | EP | claimed |
| US-20190040008-A1 | SMALL MOLECULE LFA-1 INHIBITORS | ALLOCYTE PHARMACEUTICALS AG (CH) | 2019-02-07 | — | — | US | claimed |
| US-10077238-B2 | Small molecule LFA-1 inhibitors | ALLOCYTE PHARMACEUTICALS AG (CH) | 2018-09-18 | — | — | US | claimed |
| US-20170121284-A1 | SMALL MOLECULE LFA-1 INHIBITORS | ALLOCYTE PHARMACEUTICALS AG (CH) | 2017-05-04 | — | — | US | claimed |
| EP-3154941-A1 | SMALL MOLECULE LFA-1 INHIBITORS | AlloCyte Pharmaceuticals AG (CH) | 2017-04-19 | — | — | EP | claimed |
| WO-2015189265-A1 | SMALL MOLECULE LFA-1 INHIBITORS | ALLOCYTE PHARMACEUTICALS AG (CH) | 2015-12-17 | — | — | WO | claimed |
| EP-2049536-A2 | POLYCYCLIC VIRAL INHIBITORS | GENELABS TECHNOLOGIES, INC. (US) | 2009-04-22 | — | — | EP | claimed |
| EP-2044083-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2009-04-08 | — | — | EP | claimed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | claimed |
| US-20080045498-A1 | POLYCYCLIC VIRAL INHIBITORS | GENELABS TECHNOLOGIES, INC. | 2008-02-21 | — | — | US | claimed |
| US-6541499-B1 | Antithrombotic agents | ELI LILLY AND COMPANY | 2003-04-01 | — | — | US | claimed |
| US-6271227-B1 | ANTICOAGULANTS | ELI LILLY AND COMPANY | 2001-08-07 | — | — | US | claimed |
| EP-1019047-A4 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2001-06-13 | — | — | EP | claimed |
| US-6180631-B1 | PREVENTING AND TREATING SERINE/THREONINE PROTEIN KINASE-RELATED ABNORMAL CONDITIONS IN MAMMALS ASSOCIATED WITH AN ABERRATION IN A SIGNAL TRANSDUCTION PATHWAY SUCH AS CANCER OR A FIBROTIC DISORDER | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 2001-01-30 | — | — | US | claimed |
| EP-1019047-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-07-19 | — | — | EP | claimed |
| EP-0980366-A4 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2000-05-17 | — | — | EP | claimed |
| EP-0980366-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-02-23 | — | — | EP | claimed |
| WO-1998049160-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1998-11-05 | — | — | WO | claimed |
| WO-1998048800-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1998-11-05 | — | — | WO | claimed |
| US-5021439-A | Senile dementia and memory dysfunction | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-06-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045498-A1 | POLYCYCLIC VIRAL INHIBITORS | EIF2AK2, ZC3HAV1, MAVS | ALDH1A1 2784/4885TSHR 4802/4885TP53 1790/4885 |
| US-10077238-B2 | Small molecule LFA-1 inhibitors | ICAM1, VCAM1, ITGB1 | ALDH1A1 153/4885TSHR 2988/4885TP53 685/4885 |
| US-20190040008-A1 | SMALL MOLECULE LFA-1 INHIBITORS | ICAM1, VCAM1, ITGB1 | ALDH1A1 153/4885TSHR 2988/4885TP53 685/4885 |
| US-20170121284-A1 | SMALL MOLECULE LFA-1 INHIBITORS | ICAM1, VCAM1, ITGB1 | ALDH1A1 153/4885TSHR 2988/4885TP53 685/4885 |
| US-20080051384-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | ALDH1A1 1357/4885TSHR 4492/4885TP53 3049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.